logo

The Medicines Co. (MDCO)



Trade MDCO now with
  Date
  Headline
9/25/2019 7:06:58 AM The Medicines Co Announces Positive Topline Results For ORION-10 Phase 3 Study Of Inclisiran In ASCVD Patients
9/2/2019 3:00:10 AM Medicines Co. Presents Results From ORION-11 Study Of Inclisiran
8/26/2019 7:05:29 AM The Medicines Co. Reports Positive Topline Results From First Pivotal Phase 3 Trial Of Inclisiran
7/24/2019 7:20:35 AM The Medicines Co. Q2 Loss From Cont Ops $60.1 Mln Or $0.80 Per Share
6/25/2019 11:17:25 PM Medicines Co. Prices Public Offering Of 4.55 Mln Shares At $33.00/shr
12/13/2018 9:51:43 PM The Medicines Company Prices $150 Mln Of Convertible Notes
12/11/2018 7:26:12 AM The Medicines Company Appoints Mark Timney As CEO
11/8/2018 7:15:57 AM The Medicines Co. Q3 Loss/shr From Cont. Ops. Widens To $0.70 From $0.10 Last Year
8/1/2018 7:21:19 AM The Medicines Co. Q2 Loss/shr Narrows To $0.74 From $5.53 Last Year
6/26/2018 7:28:42 AM Medicines Co Announces Presentation Of New Data From ORION-1 Phase II Trial At ADA 2018
5/7/2018 10:50:45 AM Medicines Reports Inclisiran Data Showing Reductions In Harmful Subtypes Of Bad Cholesterol On Heart Attack And Stroke
4/25/2018 7:16:50 AM Medicines Co. Q1 Loss From Cont Ops $84.8 Mln Or $1.14 Per Share
3/27/2018 9:25:56 PM Medicines Company Names Christopher Visioli As CFO, Succeeding William O'Connor
1/8/2018 7:20:53 AM The Medicines Company Announces Closing Of Divestiture Of Infectious Disease Business Unit To Melinta Therapeutics
1/8/2018 7:11:43 AM Melinta Therapeutics Completes Acquisition Of The Medicines Company’s Infectious Disease Business
  
 
>